ORYZON will participate at the 5th Annual EpiCongress in Boston, Massachusetts
Epigenetic drug discovery is exploding across the industry.
Oryzon Genomics SA will participate at the 5th Annual EpiCongress, Boston. This meeting is a premier networking, interactive and solution-led conference that addresses how understanding the mechanisms behind genome regulation and chromatin function can help provide new therapies. The meeting will be held from Wednesday July 23rd 2014 till Thursday July 24th 2014 at the Hyatt Regency Cambridge 575 Memorial Drive, Cambridge, MA 02139, USA.
Dr. Carlos Buesa, CEO of Oryzon, will present the communication ORY-1001, the First Specific LSD1 Inhibitor in Acute Myeloid Leukemia Therapy in the Session “The Challenges of Clinical Phase Trials” to be held on July 23th. On the same day Oryzon will participate in the panel Interactive Solution Finding: How do You Approach Clinical Trials Successfully? Additionally Dr. Tamara Maes, CSO of Oryzon, will act as moderator at one of the EpiC roundtable discussions at the meeting.